Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Operating Income of -$145.82 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$145.82M | -80.3% |
| 2024 | -$80.86M | -193853.3% |
| 2023 | -$41.7K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$49.18M | -150.1% | -4283.9% |
| June 30, 2025 | -$1.12M | -636.4% | +53.7% |
| March 31, 2025 | -$2.42M | -3529.9% | +87.7% |
| September 30, 2024 | -$19.66M | — | -12807.7% |
| June 30, 2024 | -$152.3K | — | -128.4% |
| March 31, 2024 | -$66.7K | — | — |
- BridgeBio Oncology Therapeutics, Inc. showed a decrease of -80.3% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, BridgeBio Oncology Therapeutics, Inc.’s operating income has declined by 349653.0% (from -$41.7 thousand to -$145.82 million).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: